Stereotactic body radiation therapy for prostate cancer

Future Oncology

Volumn 7, Issue 9, 2011, Pages 1077-1086

  Ishiyama, Hiromichi ^a,b   Teh, Bin S ^a   Lo, Simon S ^c   Mathews, Thomas ^a   Blanco, Angel ^a   Amato, Robert ^d   Ellis, Rodney J ^c   Mayr, Nina A ^e   Paulino, Arnold C ^a   Xu, Bo ^a   Butler, Brian E ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

outcome; prostate cancer; stereotactic body radiation therapy; toxicity

Indexed keywords

CANCER CELL; CANCER CELL CULTURE; CANCER CONTROL; CANCER RADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPOFRACTIONATION RADIATION THERAPY; IN VITRO STUDY; IN VIVO STUDY; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THREE DIMENSIONAL IMAGING; UROGENITAL TRACT DISEASE;

ANIMALS; DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY;

EID: 80052975026     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.86     Document Type: Review

References (53)

1. Potters L, Steinberg M, Rose C et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 60(4), 1026-1032 (2004). (Pubitemid 39440785)
2. Billy W, Loo JYC, Dawson LA et al. Stereotactic ablative radiotherapy: what's in a name? Practical Radiation Oncol. 1(1), 38-39 (2011).
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
4. Lotan Y, Stanfield J, Cho LC et al. Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J. Urol. 175(5), 1932-1936 (2006).
5. Teh BS, Gao Y, Wang X et al. In vitro and in vivo efficacy of ablative hypfractionation radiation/stereotactic body radiation therapy (SBRT) for human prostate cancer. Proc. Radiological Soc. North America Annual Meeting. Abstract SSA22-01, (2008).
6. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology, 36(2), 107-111 (1990). (Pubitemid 20239018)
7. Lukka H, Hayter C, Julian JA et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol. 23(25), 6132-6138 (2005).
8. Soete G, Arcangeli S, De Meerleer G et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother. Oncol. 80(1), 78-81 (2006). (Pubitemid 44205307)
9. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp. 2010.07.1984 (2010) (Epub ahead of print).
10. Livsey JE, Cowan RA, Wylie JP et al Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1254-1259 (2003). (Pubitemid 37443962)
11. Akimoto T, Muramatsu H, Takahashi M et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int. J. Radiat. Oncol. Biol. Phys. 60(4), 1033-1039 (2004). (Pubitemid 39440786)
12. Rene N, Faria S, Cury F et al. Hypofractionated radiotherapy for favourable risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(3), 805-810 (2010).
13. Pollack A, Hanlon AL, Horwitz EM et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 518-526 (2006). (Pubitemid 43083441)
14. Pollack A, Buyyounouski M, Horwitz E et al. Hypofractionation for prostate cancer: interim results of a randomized trial. Int. J. Radiation Oncol. Biol. Phys. 75(3), S81-S82 (2009).
15. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1424-1430 (2007). □ Important prospective Phase II clinical trials addressing SBRT for prostate cancer. (Pubitemid 47176809)
16. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective Phase II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1043-1048 (2009).
17. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front. Radiat. Ther. Oncol. 40, 395-406 (2007).
18. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 78(2), 442-448 (2010). □ Clinical trial of SBRT for prostate cancer with 5-year outcome.
19. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol, 6, 3 (2011).
20. □□ First clinical trial of SBRT for prostate cancer. 20. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1099-1105 (2007).
21. Tang CI, Loblaw DA, Cheung P et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin. Oncol. (R. Coll. Radiol.) 20(10), 729-737 (2008).
22. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol. Cancer Res. Treat. 8(5), 387-392 (2009).
23. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 10, 1 (2010).
24. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol. Cancer Res. Treat. 9(5), 473-477 (2010). □□ Important prospective Phase I clinical trial addressing toxicity of dose escalation in SBRT for prostate cancer.
25. Boike TP, Lotan Y, Cho LC et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediaterisk prostate cancer. J. Clin. Oncol. 29(15), 2020-2026 (2011).
26. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Cancer Res. Treat. 9(6), 575-582 (2010).
27. Jabbari S, Weinberg VK, Kaprealian T et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp. 2010.10.026 (2010).
28. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43(5), 1095-1101 (1999). □□ Important review paper on α:β value for prostate cancer. (Pubitemid 29144800)
29. Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials? Clin. Oncol. (R. Coll. Radiol.) 19(5), 289-301 (2007). (Pubitemid 46760594)
30. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin. Radiat. Oncol. 18(4), 249-256 (2008).
31. Martinez AA, Gonzalez J, Ye H et al. Dose escalation improves cancer-related events at 10 years for intermediate-and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 79(2), 363-370 (2011).
32. Brenner D, Armour E, Corry P, Hall E. Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): implications for new brachytherapy protocols. Int. J. Radiat. Oncol. Biol. Phys. 41(1), 135-138 (1998). (Pubitemid 28211313)
33. van der Kogel AJ, Jarrett KA, Paciotti MA, Raju MR. Radiation tolerance of the rat rectum to fractionated X-rays and pi-mesons. Radiother. Oncol. 12(3), 225-232 (1988).
34. Dewit L, Oussoren Y, Bartelink H, Thames HD. The effect of cis-diamminedichloroplatinum (II) on radiation damage in mouse rectum after fractionated irradiation. Radiother. Oncol. 16(2), 121-128 (1989). (Pubitemid 19258951)
35. Terry NH, Denekamp J. RBE values and repair characteristics for colo-rectal injury after caesium 137 γ-ray and neutron irradiation. II. Fractionation up to ten doses. Br. J. Radiol. 57(679), 617-629 (1984). (Pubitemid 14121800)
36. Dubray BM, Thames HD. Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume. Radiother. Oncol. 33(1), 41-47 (1994). (Pubitemid 24362143)
37. Gasinska A, Dubray B, Hill SA, Denekamp J, Thames HD, Fowler JF. Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation. Radiother. Oncol. 26(3), 244-253 (1993). (Pubitemid 23132293)
38. Brenner DJ. Fractionation and late rectal toxicity. Int. J. Radiat. Oncol. Biol. Phys. 60(4), 1013-1015 (2004). (Pubitemid 39440782)
39. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56(4), 1093-1104 (2003). (Pubitemid 36794043)
40. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70(3), 847-852 (2008). (Pubitemid 351199730)
41. Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA. A generalized linear-quadratic mode for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci. Transl. Med. 2(39), 39ra48 (2010).
42. Schubert LK, Westerly DC, Tome WA et al. A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3, 800 helical tomotherapy treatments. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1260-1269 (2009).
43. Zhou J, Uhl B, Dewit K et al. Analysis of daily setup variation with tomotherapy megavoltage computed tomography. Med. Dosim. 35(1), 31-37 (2010).
44. Kupelian PA, Lee C, Langen KM et al. Evaluation of image-guidance strategies in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(4), 1151-1157 (2008). (Pubitemid 351296109)
45. Langen KM, Jones DT. Organ motion and its management. Int. J. Radiat. Oncol. Biol. Phys. 50(1), 265-278 (2001).
46. Balter JM, Sandler HM, Lam K, Bree RL, Lichter AS, ten Haken RK. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int. J. Radiat. Oncol. Biol. Phys. 31(1), 113-118 (1995).
47. Buyyounouski MK, Price RA Jr, Harris EE et al. Stereotactic body radiotherapy for primary management of early-stage, low-to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int. J. Radiat. Oncol. Biol. Phys. 76(5), 1297-1304 (2010).
48. Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol. 7(1), 44-54 (2010).
49. Teh BS, Paulino AC, Lu HH et al. Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol. Cancer Res. Treat. 6(4), 347-354 (2007). (Pubitemid 47340128)
50. Perez CA. Principles and Practice of Radiation Oncology. Lippincott Williams & Wilkins, PA, USA (2004).
51. Maciejewski B. Boost in radiotherapy: external beam sunset, brachytherapy sunrise. J. Contemp. Brachytherapy 1(1), 5-10 (2009).
52. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J. Clin. Oncol. DOI:10.1016/j. ijrobp. 2009.07.1015 (2010) (Epub ahead of print).
53. Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. DOI:10.1016/j.ijrobp. 2010.10.074 (2011) (Epub ahead of print).